Mass spectrometry-based proteomics of FFPE tissues: progress, limitations, and clinical translation barriers

Clinical Proteomics · Published 2025-11-28 · DOI 10.1186/s12014-025-09567-z

Authors being retrieved — see the publisher record. https://doi.org/10.1186/s12014-025-09567-z

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids · Clinical Proteomics · 2026 · Same journal
Plasma protein signatures altered before and after tuberculosis diagnosis in a population-based cohort · Clinical Proteomics · 2026 · Same journal
Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer · Clinical Proteomics · 2026 · Same journal
Quantitative tandem mass tag-based serum proteomics for longitudinal biomarker monitoring in Duchenne muscular dystrophy · Clinical Proteomics · 2026 · Same journal
Evaluation of the relationship between inflammation and typical chest pain in ST-elevation myocardial infarction · Clinical Proteomics · 2026 · Same journal
Nipple aspirate fluid as a proximal breast liquid biopsy platform: advancing precision risk management in breast cancer · Clinical Proteomics · 2026 · Same journal
Distinct proteomic profiles of clinical isolates show diversity of Pseudomonas aeruginosa colistin-resistance · Clinical Proteomics · 2026 · Same journal
Diffusing capacity for carbon monoxide is significantly associated with cardiovascular disease-related plasma proteins, independently of obstruction · Clinical Proteomics · 2026 · Same journal
Quantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis · Clinical Proteomics · 2026 · Same journal
A succinylation-related prognostic model for predicting lung adenocarcinoma prognosis and guiding immunotherapy · Clinical Proteomics · 2026 · Same journal